457 related articles for article (PubMed ID: 18477623)
1. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
O'Keane V
J Psychopharmacol; 2008 Mar; 22(2 Suppl):70-5. PubMed ID: 18477623
[TBL] [Abstract][Full Text] [Related]
2. Hyperprolactinaemia and antipsychotic therapy in schizophrenia.
Hummer M; Huber J
Curr Med Res Opin; 2004; 20(2):189-97. PubMed ID: 15006013
[TBL] [Abstract][Full Text] [Related]
3. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
Haddad PM; Wieck A
Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
[TBL] [Abstract][Full Text] [Related]
5. [Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy].
Riecher-Rössler A; Schmid C; Bleuer S; Birkhäuser M
Neuropsychiatr; 2009; 23(2):71-83. PubMed ID: 19573500
[TBL] [Abstract][Full Text] [Related]
6. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.
Holt RI
J Psychopharmacol; 2008 Mar; 22(2 Suppl):28-37. PubMed ID: 18477618
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management.
Holt RI; Peveler RC
Clin Endocrinol (Oxf); 2011 Feb; 74(2):141-7. PubMed ID: 20455888
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic-induced hyperprolactinaemia in patients with schizophrenia: considerations in relation to bone mineral density.
Stubbs B
J Psychiatr Ment Health Nurs; 2009 Nov; 16(9):838-42. PubMed ID: 19824978
[TBL] [Abstract][Full Text] [Related]
9. Prolactin awareness: an essential consideration for physical health in schizophrenia.
Montejo AL
Eur Neuropsychopharmacol; 2008 May; 18 Suppl 2():S108-14. PubMed ID: 18346598
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic-induced hyperprolactinaemia.
Inder WJ; Castle D
Aust N Z J Psychiatry; 2011 Oct; 45(10):830-7. PubMed ID: 21714721
[TBL] [Abstract][Full Text] [Related]
11. Hormonal side effects in women: typical versus atypical antipsychotic treatment.
Dickson RA; Seeman MV; Corenblum B
J Clin Psychiatry; 2000; 61 Suppl 3():10-5. PubMed ID: 10724128
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?
O'Keane V; Meaney AM
J Clin Psychopharmacol; 2005 Feb; 25(1):26-31. PubMed ID: 15643097
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic-induced hyperprolactinemia and sexual dysfunction.
Compton MT; Miller AH
Psychopharmacol Bull; 2002; 36(1):143-64. PubMed ID: 12397853
[TBL] [Abstract][Full Text] [Related]
14. Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication.
Meaney AM; O'Keane V
J Psychopharmacol; 2003 Dec; 17(4):455-8. PubMed ID: 14870961
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic-induced hyperprolactinemia.
Bostwick JR; Guthrie SK; Ellingrod VL
Pharmacotherapy; 2009 Jan; 29(1):64-73. PubMed ID: 19113797
[TBL] [Abstract][Full Text] [Related]
16. [Hyperprolactinaemia and bone mineral density].
Kostrzak A; Męczekalski B
Pol Merkur Lekarski; 2015 Aug; 39(230):122-5. PubMed ID: 26319389
[TBL] [Abstract][Full Text] [Related]
17. The evolution of hyperprolactinaemia as an entity in psychiatric patients.
Kohen D; Wildgust HJ
J Psychopharmacol; 2008 Mar; 22(2 Suppl):6-11. PubMed ID: 18477616
[TBL] [Abstract][Full Text] [Related]
18. A review of the association between antipsychotic use and hyperprolactinaemia.
Bushe C; Shaw M; Peveler RC
J Psychopharmacol; 2008 Mar; 22(2 Suppl):46-55. PubMed ID: 18477620
[TBL] [Abstract][Full Text] [Related]
19. Hyperprolactinaemia caused by antipsychotic drugs. Endocrine antipsychotic side effects must be systemically assessed.
Howes O; Smith S
BMJ; 2002 May; 324(7348):1278. PubMed ID: 12028991
[No Abstract] [Full Text] [Related]
20. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.
Meaney AM; Smith S; Howes OD; O'Brien M; Murray RM; O'Keane V
Br J Psychiatry; 2004 Jun; 184():503-8. PubMed ID: 15172944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
